Price of domestic targeted drug Sotorasib

Sotorasib (Sotorasib) is a revolutionary anti-cancer drug and belongs to the new generation of KRAS G12C inhibitors. Its development is a major breakthrough in the field of cancer treatment for a long time. Especially in patients with non-small cell lung cancer (NSCLC), drugs against KRASgene G12C mutations have always been a difficult problem that scientists work hard to overcome.

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.

Sotoracib is unique in its ability to directly interfere with the KRAS G12C mutation, a genetic mutation that is widespread in many cancers. KRASThe gene plays a key role in regulating cell growth and differentiation, and its mutations cause cells to lose normal growth control, leading to the occurrence of cancer. By specifically inhibiting the KRAS G12C mutation, sotoracib effectively blocks the growth signaling pathway of cancer cells, thereby inhibiting the development of tumors.

Clinical trial results show that sotorasiib has a significant therapeutic effect in some KRAS G12C mutated NSCLC patients, bringing new treatment options to this patient group. This drug not only marks a huge breakthrough in the field of KRAS gene therapy, but also provides hope for patients who were once considered difficult to treat.